Hamburg, November 30, 2020 – The Research Institute Children’s Cancer Center Hamburg was delighted to receive a donation of 20,000 Euros from the Eppendorf Group. The money was presented to Professor Dr. Ulrich Schüller of the Research Institute Children’s Cancer Center Hamburg on the previous Thursday, November 26, 2020. The institute studies leukemias, brain tumors and neuroblastomas – the most prevalent of all childhood cancers.
“Eppendorf has been supporting medical research and development with its instruments, consumables and services for the past 75 years, and it also fulfills its societal responsibilities through manifold social activities. With the current donation of 20,000 Euros that will benefit the Research Institute Children’s Cancer Center Hamburg, the Eppendorf Group illustrates this commitment in an impressive manner”, explains Eva van Pelt, Co-Chairperson of the Board at Eppendorf AG. “In this difficult year at Christmas, it was important to us to contribute for the first time to a worthy cause that is closely connected to our company mission – to improve the living conditions for all people.” Understandably, global attention currently focuses on the development of vaccines against the coronavirus, continues van Pelt; however, basic medical research, as well as applied research, must not be neglected. It is imperative to continue to conquer illnesses such as cancer, dementia or Parkinson. The donation is intended to specifically contribute to this goal.
Professor Dr. Ulrich Schüller of the Research Institute Children’s Cancer Center Hamburg appreciated the generous financial support: “Our gratitude goes out to the Eppendorf Group which, with their substantial donation, will enable state-of-the-art research. Malignant tumors are among the second most frequent cancers in children and adolescents; yet many types of brain tumor have not been studied in depth and continue to be difficult to treat to this day. At our institute, we study the mechanisms through which cancers in children emerge, in order to develop novel approaches for improved and targeted therapies.”
For the past five years, Professor Dr. Ulrich Schüller has been researching developmental neurobiology and pediatric neuro-oncology. Together with his group, he aims to advance diagnostics as well as pave the way for new therapies. In close collaboration with the Clinic for Pediatric Hematology and Oncology at the University Hospital Eppendorf, Professor Schüller interprets his research in the light of clinical disease progression – always with the goal of transferring promising findings to the clinic as rapidly as possible.
Image see attachment: 2020_11_26_Spendenuebergabe_Kinderkrebs-Zentrum_Eppendorf.jpg
Caption: Professor Dr. Ulrich Schüller (left) is pleased to receive the 20,000 Euro cheque that Dr. Ralph Esper (right), Head of Corporate Communications at Eppendorf AG, is presenting on behalf of the Eppendorf Group.
Dr. Ralph Esper
Tel.: +49 40 538 01-195
Tel.: +49 40 538 01-616
Eppendorf AG is a leading company in the Life Sciences that develops and sells instruments, consumables and services for liquid handling, sample handling, and cell handling for use in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges and mixers, spectrometers and DNA amplification equipment as well as ultra-low temperature freezers, fermenters, bioreactors, CO2 incubators, shakers and cell manipulation systems. Consumables such as pipette tips, test tubes, microliter plates and single-use bioreactor vessels complement the range of highest-quality premium products.
Eppendorf products are employed in academic as well as commercial research laboratories, for example in companies of the pharmaceutical and biotechnological as well as the chemical and food industries. In addition, clinical and environmental analysis laboratories, and forensics and industrial laboratories performing process analysis, production, and quality assurance utilize Eppendorf products.
Eppendorf was founded in 1945 with headquarters located in Hamburg and today employs approximately 4,000 employees worldwide. The company owns subsidiaries in 26 countries and is represented through distributors in all its important markets.
About the Research Institute Children’s Cancer Center Hamburg
At the Research Institute Children’s Cancer Center Hamburg, studies focus on the mechanisms through which cancers in children emerge in order to develop novel approaches for improved and targeted therapies. To this end, the Institute, with two endowment professorships and four research working groups, concentrates on areas that are vital to children suffering from cancer: leukemia and brain tumors, the most common cancers of childhood, as well as neuroblastomas – immature tumors of the nervous system that almost exclusively affect children, and the optimization of stem cell transplants, one of the most important treatment methods in the fight against cancer.
The Research Institute Children’s Cancer Center Hamburg was founded in 2006 by the Foundation of the Children’s Cancer Center Hamburg as a charitable non-profit limited company. The Institute is financed through donations and sponsorships. At this time, approximately one third of the project costs are covered through competitive external funding by the German Research Foundation (DFG), the German Cancer Aid (Deutsche Krebshilfe), the Federal Ministry of Education and Research (BMBF), the European Union (EU) and other third party donors. To us, this signifies an important confirmation of the quality of our research.
The young institute is accompanied by an international scientific advisory committee, and it works in close collaboration with the University Hospital Hamburg-Eppendorf (UKE).
Additional information about the Research Institute Children’s Cancer Center Hamburg is available at: kinderkrebs-forschung.de